CUREVAC
CureVac is a clinical-stage biopharmaceutical company that provides prophylactic and therapeutic application of messenger RNA. The company develops drugs that are based on Messenger RNA (mRNA) as a data carrier to instruct the human body to produce its own proteins capable of fighting a wide range of diseases. mRNA programs include novel mRNA-based cancer immunotherapies and prophylactic vaccines against infectious diseases (RNActive), molecular therapies designed to trigger the body’s own production of therapeutic proteins (RNArt), and RNA encoded antibodies (RNAntibody). Its most advanced product candidate, CV9104, is being developed in Phase IIb for the treatment of prostate cancer.
CUREVAC
Industry:
Biopharma Biotechnology Therapeutics
Founded:
2000-01-01
Address:
Tübingen, Baden-Wurttemberg, Germany
Country:
Germany
Website Url:
http://www.curevac.com
Total Employee:
251+
Status:
Active
Contact:
+49707198830
Email Addresses:
[email protected]
Total Funding:
1.85 B USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API Google Analytics Apple Mobile Web Clips Icon Google Tag Manager WordPress Content Delivery Network
Similar Organizations
Chiasma
Chiasma is a biopharmaceutical company developing oral drugs for the treatment of orphan diseases.
Current Advisors List
Current Employees Featured
Founder
Stock Details
Acquisitions List
| Date | Company | Article | Price |
|---|---|---|---|
| 2022-06-08 | Frame Cancer Therapeutics | Frame Cancer Therapeutics acquired by CureVac | 32 M EUR |
Investors List
German Federal Ministry of Education and Research (BMBF)
German Federal Ministry of Education and Research (BMBF) investment in Grant - CureVac
Qatar Investment Authority
Qatar Investment Authority investment in Venture Round - CureVac
GlaxoSmithKline
GlaxoSmithKline investment in Corporate Round - CureVac
European Investment Bank
European Investment Bank investment in Debt Financing - CureVac
KfW
KfW investment in Venture Round - CureVac
LBBW Asset Management
LBBW Asset Management investment in Series F - CureVac
Baden-Württembergische Versorgungsanstalt für Ärzte
Baden-Württembergische Versorgungsanstalt für Ärzte investment in Series F - CureVac
Landeskreditbank Baden-Württemberg
Landeskreditbank Baden-Württemberg investment in Series F - CureVac
Baillie Gifford
Baillie Gifford investment in Series F - CureVac
Chartwave
Chartwave investment in Series F - CureVac
Key Employee Changes
| Date | New article |
|---|---|
| 2020-08-04 | Curevac names Franz-Werner Haas as CEO |
Official Site Inspections
http://www.curevac.com Semrush global rank: 241.55 K Semrush visits lastest month: 291.99 K
- Host name: dedi3042.your-server.de
- IP address: 188.40.29.42
- Location: Germany
- Latitude: 51.2993
- Longitude: 9.491
- Timezone: Europe/Berlin
More informations about "CureVac"
CureVac - Wikipedia
CureVac N.V. is a German biopharmaceutical company. It develops therapies based on messenger RNA (mRNA). Headquartered in Tübingen, Germany, the company was founded in 2000 by Ingmar Hoerr (CEO), Steve Pascolo (CSO), Florian von der Mulbe (COO), Günther Jung, and Hans-Georg Rammensee. CureVac has had approximately 375 employees since May 2018. See details»
About Us - CureVac
With a single discovery, CureVac opened the world up to the potential of mRNA to treat diseases and create vaccines. Officially founded in 2000, CureVac is the world’s first company to successfully harness mRNA for medical …See details»
CureVac - Crunchbase Company Profile & Funding
CureVac is a clinical-stage biopharmaceutical company that provides prophylactic and therapeutic application of messenger RNA. The company develops drugs that are based on Messenger RNA (mRNA) as a data carrier to instruct the …See details»
CureVac - Wir revolutionieren die mRNA für das Leben …
Großaktionäre, die mindestens 5 Prozent einer CureVac-Aktie besitzen, müssen ihre Verkäufe und Käufe der SEC offenlegen. Aktuelle Pressemitteilungen. 12. November 2024. CureVac veröffentlicht Finanzergebnisse für das dritte …See details»
CureVac - LinkedIn
CureVac | 52,376 followers on LinkedIn. We fight for human health - we are the RNA people | CureVac (Nasdaq: CVAC) is a pioneering multinational biotech company founded in 2000 to advance the ...See details»
CureVac - Funding, Financials, Valuation & Investors - Crunchbase
CureVac is registered under the ticker NASDAQ:CVAC . Their stock opened with $16.00 in its Aug 14, 2020 IPO. CureVac is funded by 16 investors. German Federal Ministry of Education …See details»
CureVac Company Profile - Office Locations, Competitors ... - Craft
Oct 29, 2024 CureVac has 5 employees across 6 locations and €53.76 m in annual revenue in FY 2023. See insights on CureVac including office locations, competitors, revenue, financials, …See details»
GSK and CureVac to Restructure Collaboration into New Licensing …
Jul 3, 2024 CureVac will receive an upfront payment of €400 million and up to an additional €1.05 billion in development, regulatory and sales milestones and tiered royalties in the high …See details»
CureVac Initiates Strategic Restructuring to Align Resources
Jul 3, 2024 TÜBINGEN, GERMANY and BOSTON, MA/ ACCESSWIRE/ July 3, 2024/ CureVac N.V., a global biopharmaceutical company developing a new class of transformative medicines …See details»
Corporate Governance - CureVac
Birgit Hofmann is an accomplished leader in environmental innovations, electromobility, and battery technology, currently heading the respective department at the German Federal …See details»
GSK and CureVac to restructure collaboration into new licensing ...
Jul 3, 2024 CureVac will receive an upfront payment of €400 million and up to an additional €1.05 billion in development, regulatory and sales milestones and tiered royalties in the high …See details»
CureVac AG - Devex
Learn more about CureVac AG's jobs, projects, latest news, contact information and geographical presence. CureVac – Where the Pioneering Spirit Meets Expert KnowledgeLike many …See details»
CureVac
From day one, people have always been central to CureVac’s mission — after all, we are on a mission to use therapeutic mRNA to transform people’s lives. That’s why we are dedicated to …See details»
CureVac Initiates Strategic Restructuring to Align Resources with …
Jul 3, 2024 CureVac N.V. (Nasdaq: CVAC) (“CureVac”), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid …See details»
CureVac Initiates Strategic Restructuring to Align Resources with …
Jul 3, 2024 The cost savings, combined with an upfront payment of €400 million and up to €1.05 billion in milestones plus tiered royalties from the GSK agreement, will extend CureVac's cash …See details»
CureVac COVID-19 vaccine - Wikipedia
The CureVac COVID-19 vaccine (abbreviated CVnCoV) was a COVID-19 vaccine candidate developed by CureVac N.V. and the Coalition for Epidemic Preparedness Innovations (CEPI). …See details»
Overview - CureVac
Nov 12, 2024 The Annual General Meeting (the “AGM”) of Shareholders of CureVac N.V. (the “Company”) was held on Thursday, June 24, 2021, at 2:00 p.m. Central European Summer …See details»
CureVac N.V. (CVAC) Stock Price, News, Quote & History - Yahoo …
CureVac N.V., a biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic …See details»
COVID-19 - CureVac
Activities regarding CVnCoV, CureVac's mRNA-based vaccine candidate against COVID-19 The COVID-19 pandemic poses one of the greatest challenges humankind has faced this century. …See details»